Publications and communications of Lucia MUSUMECI

Leeten, K., Jacques, N., Esquembre, L. A., Schneider, D. C., Straetener, J., Henriksen, C., MUSUMECI, L., Putters, F., Ferreira Melo, S., Sánchez-López, E., Giera, M., Penoy, N., Piel, G., Verlaine, O., Amoroso, A., Joris, B., Slavetinsky, C. J., Goffin, E., Pirotte, B., ... Oury, C. (2024). Ticagrelor alters the membrane of Staphylococcus aureus and enhances the activity of vancomycin and daptomycin without eliciting cross-resistance. MBio, 0132224. doi:10.1128/mbio.01322-24

Praca, C., Sakalihasan, N., Defraigne, J.-O., Labropoulos, N., Albert, A., Seidel, L., & MUSUMECI, L. (17 June 2024). Endovascular Treatment of Abdominal Aortic Aneurysm: Impact of Diabetes on Endoleaks and Reintervention. Journal of Clinical Medicine, 13 (12), 3551. doi:10.3390/jcm13123551

Brüls, S., MUSUMECI, L., Courtois, A., Hustinx, R., SAKALIHASAN, S., Namur, G., Defraigne, J.-O., & Sakalihasan, N. (22 April 2024). Can Biomarkers and PET Imaging Predict Abdominal Aortic Aneurysm Growth Rate? Journal of Clinical Medicine, 13 (8), 2448. doi:10.3390/jcm13082448

Khbouz, B., MUSUMECI, L., Grahammer, F., & Jouret, F. (2024). The Dual-specificity Phosphatase 3 (DUSP3): A Potential Target Against Renal Ischemia/Reperfusion Injury. Transplantation. doi:10.1097/TP.0000000000005009

Sakalihasan, N., Brüls, S., Hustinx, R., Tchana-Sato, V., SAKALIHASAN, S., Hultgren, R., Labropoulos, N., Colige, A., Durieux, R., Drion, P., Albert, A., Defraigne, J.-O., & MUSUMECI, L. (09 March 2024). Association between PET/CT Scan Findings, Treatment, and Cancer Incidence in a Cohort of AAA Patients. Journal of Clinical Medicine, 13 (6), 1569. doi:10.3390/jcm13061569

Pincemail, J.* , Tchana-Sato, V.* , Courtois, A., MUSUMECI, L., CHERAMY-BIEN, J.-P., Munten, J., Labropoulos, N., Defraigne, J.-O., & Sakalihasan, N. (16 May 2023). Alteration of Blood Oxidative Stress Status in Patients with Thoracic Aortic Dissection: A Pilot Study. Antioxidants, 12 (5), 1106. doi:10.3390/antiox12051106

Lancellotti, P., Aqil, A., MUSUMECI, L., Jacques, N., Ditkowski, B., Debuisson, M., Thiry, M., Dupont, J., Gougnard, A., Sandersen, C., CHERAMY-BIEN, J.-P., Sakalihasan, N., Nchimi Longang, A., Detrembleur, C., Jérôme, C., & Oury, C. (2023). Bioactive surface coating for preventing mechanical heart valve thrombosis. Journal of Thrombosis and Haemostasis. doi:10.1016/j.jtha.2023.05.004

Oury, C., Meyers, S., Jacques, N., Leeten, K., Jiang, Z., MUSUMECI, L., Lox, M., Debuisson, M., Goffin, E., Pirotte, B., Delvenne, P., Nchimi Longang, A., Hubert, C., Heptia, M., Hubert, P., Kuijpers, M. J. E., Vanassche, T., Martinod, K., Verhamme, P., & Lancellotti, P. (2023). Protective Effect of Ticagrelor Against Infective Endocarditis Induced by Virulent Staphylococcus aureus in Mice. JACC: Basic to Translational Science. doi:10.1016/j.jacbts.2023.02.003

MUSUMECI, L., Eilenberg, W., Pincemail, J., Yoshimura, K., & Sakalihasan, N. (29 November 2022). Towards Precritical Medical Therapy of the Abdominal Aortic Aneurysm. Biomedicines, 10 (12), 3066. doi:10.3390/biomedicines10123066

LANCELLOTTI, P., Oury, C., Pirotte, B., MUSUMECI, L., Jacques, N., & Goffin, E. (23 September 2021). Preparation of pyrimidine derivatives for prevention and treatment of Gram-negative bacterial infection, contamination and fouling.

Oury, C., Pirotte, B., MUSUMECI, L., Jacques, N., Goffin, E., & LANCELLOTTI, P. (22 October 2020). New pyrimidine derivatives for prevention and treatment of gram negative bacterial infection, contamination and fouling.

Goffin, E., Jacques, N., Musumeci, L., Nchimi Longang, A., Oury, C., Lancellotti, P., & Pirotte, B. (2020). Synthesis of ticagrelor analogues belonging to 1,2,3-triazolo[4,5-d]pyrimidines and study of their antiplatelet and antibacterial activity. European Journal of Medicinal Chemistry, 208, 112767. doi:10.1016/j.ejmech.2020.112767

Musumeci, L., Oury, C., & Lancellotti, P. (2020). When your heart depends on your gut feelings. Revista Española de Cardiología (English Edition). doi:10.1016/j.rec.2020.03.006

Lancellotti, P., Musumeci, L., & Oury, C. (2019). Are Antiplatelet Agents Beneficial in Prevention of Infective Endocarditis?-Reply. JAMA Cardiology. doi:10.1001/jamacardio.2019.3089

Lancellotti, P., Musumeci, L., Jacques, N., Servais, L., Goffin, E., Pirotte, B., & Oury, C. (2019). Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria. JAMA Cardiology. doi:10.1001/jamacardio.2019.1189

Oury, C., Musumeci, L., Jacques, N., & LANCELLOTTI, P. (2019). Activité antibiotique de l'antiplaquettaire ticagrelor : une nouvelle piste contre l'antibiorésistance. Vaisseaux, Coeur, Poumons, 24 (7), 8-13.

Musumeci, L., Jacques, N., Hego, A., Nchimi Longang, A., Lancellotti, P., & Oury, C. (2018). Prosthetic Aortic Valves: Challenges and Solutions. Frontiers in Cardiovascular Medicine, 5, 46. doi:10.3389/fcvm.2018.00046

Delierneux, C., Donis, N., Servais, L., Wéra, O., LECUT, C., Vandereyken, M., Musumeci, L., Rahmouni, S., Schneider, J., Eble, J., LANCELLOTTI, P., & Oury, C. (May 2017). Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides. Journal of Thrombosis and Haemostasis, 15 (5), 983-997. doi:10.1111/jth.13669

Vandereyken, M., Singh, P., Wathieu, C., Jacques, S., Zurashvili, T., Dejager, L., Amand, M., Musumeci, L., Singh, M., MOUTSCHEN, M., Libert, C., & Rahmouni, S. (2017). Dual-Specificity Phosphatase Deletion Protects Female, but Not Male, Mice from Endotoxemia- and Polymicrobial-Induced Septic Shock. Journal of Immunology. doi:10.4049/jimmunol.1602092

Dubois, N., Willems, M., Kroonen, J., Berendsen, S., Van Hecke, W., Bredel, M., Musumeci, L., Poulet, C., Chakravarti, A., Bours, V., & Robe, P. (09 September 2016). Involvement of Ikbζ in glioblastomas and its potential implication in radioresistance [Poster presentation]. Annual Mini Symposium - EDT-Cancérologie Expérimentale, Bruxelles, Belgium.

Rahmouni, S., Hego, A., Delierneux, C., Wéra, O., Musumeci, L., Tautz, L., & Oury, C. (2016). Functional analysis of protein tyrosine phosphatases in thrombosis and haemostasis. In Protein Tyrosine Phosphatases: Methods and Protocols (pp. 301-30). New York, United States: Springer Science.

Dubois, N., Willems, M., Kroonen, J., Berendsen, S., Van Hecke, W., Bredel, M., Musumeci, L., Poulet, C., Chakravarti, A., Bours, V., & Robe, P. (2016). Involvement of Ikbζ in glioblastomas and its potential implication in radioresistance [Poster presentation]. 28th EORTC-NCI-AACR symposium on "Molecular targets and cancer therapeutics", Munich, Germany.

Willems, M., Dubois, N., Musumeci, L., Bours, V., & Robe, P. (2016). IkappaBzeta: an emerging player in cancer. Oncotarget, 7 (40), 66310-66322. doi:10.18632/oncotarget.11624

Rahmouni, S., MUSUMECI, L., Kuijpers, M. J., Gilio, K., Hego, A., Theatre, E., Senis, Y., Heemskerk, J., Thiry, M., Tautz, L., & Oury, C. (24 June 2015). DUSP3 Phosphatase Deficiency or Inhibition Limits Platelet Activation and Arterial Thrombosis [Paper presentation]. ISTH 2015 Congress, Toronto, Canada.

Delierneux, C., Hego, A., LECUT, C., Vandereyken, M., MUSUMECI, L., Rahmouni, S., BOURS, V., LANCELLOTTI, P., & Oury, C. (22 June 2015). CLEC-2 is required for the activation of mouseplatelets by bacterial DNA mimetics [Paper presentation]. ISTH 2015 Congress, Toronto, Canada.

Delierneux, C., Hego, A., LECUT, C., Vandereyken, M., MUSUMECI, L., Rahmouni, S., BOURS, V., Lancellotti, P., & Oury, C. (22 June 2015). CLEC-2 is required for the activation of mouse platelets by bacterial DNA mimetics [Paper presentation]. ISTH 2015 Congress, Toronto, Canada.

Singh, P.* , Dejager, L.* , Amand, M.* , Theatre, E., Vandereyken, M., Zurashvili, T., Singh, M., Mack, M., Timmermans, S., Musumeci, L., Dejardin, E., Mustelin, T., Van Ginderachter, J. A., Moutschen, M., Oury, C., Libert, C.* , & Rahmouni, S.*. (15 May 2015). DUSP3 genetic deletion confers M2-like−macrophage-dependent tolerance to septic shock. Journal of Immunology, 194 (10), 4951-62. doi:10.4049/jimmunol.1402431

Musumeci, L., Kuijpers, M., Gilio, K., Hego, A., Theatre, E., Maurissen, L., Vandereyken, M., Diogo, C., LECUT, C., Guilmain, W., Bobkova, E., Eble, J., Dahl, R., Drion, P., Rascon, J., Mostofi, Y., Yuan, H., Sergienko, E., Chung, T., ... Rahmouni, S.*. (17 February 2015). DUSP3 Phosphatase Deficiency or Inhibition Limit Platelet Activation and Arterial Thrombosis. Circulation, 131 (7), 656-68. doi:10.1161/CIRCULATIONAHA.114.010186

Delierneux, C., Hego, A., LECUT, C., Vandereyken, M., Musumeci, L., Rahmouni, S., Thiry, M., Compère, P., BOURS, V., Lancellotti, P., & Oury, C. (27 January 2015). Bacterial DNA mimetics activate platelets and promote thrombosis via CLEC-2 [Poster presentation]. GIGA-DAY: Current advances in medical genetics and genomics, Liège, Belgium.

Amand, M., Erpicum, C., BAJOU, K., Cerignoli, F., Blacher, S., MARTIN, M., Dequiedt, F., Drion, P., Singh, P., Vandereyken, M., Musumeci, L., Moutschen, M., Gilles, C., Noël, A., & Rahmouni, S. (27 January 2014). DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase [Poster presentation]. GIGA Day 2014, Liège, Belgium.

Amand, M., Erpicum, C., BAJOU, K., Cerignoli, F., Blacher, S., Martin, M., Dequiedt, F., Drion, P., Singh, P., Zurashvili, T., Vandereyken, M., Musumeci, L., Mustelin, T., Moutschen, M., Gilles, C., Noël, A., & Rahmouni, S. (2014). DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase. Molecular Cancer. doi:10.1186/1476-4598-13-108

Musumeci, L., Maurissen, L., Kuijpers, M. J., Senis, Y., MOUTSCHEN, M., Mustelin, T., Heemskerk, J. W., Oury, C., & Rahmouni, S. (02 July 2013). Genetic deletion of Vaccinia H1-related (VHR) phosphatase inhibits collagen-induced platelet activation and thrombus formation without affecting bleeding time in mice [Paper presentation]. XXIVth Congress of the ISTH, Amsterdam, Netherlands.

Rahmouni, S., Singh, P., Dejager, L., Singh, M., Amand, M., Musumeci, L., Moutschen, M., Mustelin, T., & Libert, C. (2013). Dual-specificity phosphatase 3 knockout female mice are resistant to LPS and to polymicrobial induced septic shock in TNF dependent manner. Journal of Immunology.

Tautz, L., Vang, T., Liu, W., Delacroix, L., Wu, S., Vasile, S., Dahl, R., Yang, L., MUSUMECI, L., Francis, D., Landskron, J., Tasken, K., Tremblay, M., Lie, B., Page, R., Mustelin, T., Rahmouni, S., & Rickert, R. (April 2012). Dynamic interaction between lymphoid tyrosine phosphatase and C-terminal Src kinase controls T cell activation. FASEB Journal, 26.

Singh, M., Singh, P., Gaudray, G., Musumeci, L., Thielen, C., VAIRA, D., Vandergeeten, C., Delacroix, L., Van Gulck, E., Vanham, G., de Leval, L., Rahmouni, S., & MOUTSCHEN, M. (2012). An improved protocol for efficient engraftment in NOD/LTSZ-SCIDIL-2Rgammanull mice allows HIV replication and development of anti-HIV immune responses. PLoS ONE, 7 (6), 38491. doi:10.1371/journal.pone.0038491

Vang, Liu, W. H., Delacroix, L., Wu, S., Vasile, S., Dahl, R., Yang, L., Musumeci, L., Francis, D., Landskron, J., Tasken, T., Tremblay, M. L., Lie, B. A., Page, R., Mustelin, T., Rahmouni, S., Rickert, R. C., & Tautz, L. (2012). LYP inhibits T-cell activation when dissociated from CSK. Nature Chemical Biology. doi:10.1038/nchembio.916

Musumeci, L., Arthur, J., Cheung, F., Hoque, A., Lippman, S., & Reichardt, J. (January 2010). Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies. Human Mutation, 31 (1), 63-73. doi:10.1002/humu.21137

Musumeci, L., Bongiorni, C., Tautz, L., Edwards, R., Osterman, A., Perego, M., Mustelin, T., & Bottini, N. (July 2005). Low-Molecular-Weight Protein Tyrosine Phosphatases of Bacillus subtilis. Journal of Bacteriology, 187 (14), 4945-4956. doi:10.1128/JB.187.14.4945-4956.2005

Mijakovic, I., Musumeci, L., Tautz, L., Petranovic, D., Edwards, R., Jensen, P. R., Mustelin, T., Deutscher, J., & Bottini, N. (May 2005). In vitro characterization of the Bacillus subtilis protein tyrosine phosphatase YwqE. Journal of Bacteriology, 187 (10), 3384-90. doi:10.1128/JB.187.10.3384-3390.2005

Vang, T., Congia, M., Macis, M. D., Musumeci, L., Orru, V., Zavattari, P., Nika, K., Tautz, L., Tasken, K., Cucca, F., Mustelin, T., & Bottini, N. (2005). Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nature Genetics, 37 (12), 1317-9. doi:10.1038/ng1673

Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S., Nika, K., Rostamkhani, M., MacMurray, J., Meloni, G. F., Lucarelli, P., Pellecchia, M., Eisenbarth, G. S., Comings, D., & Mustelin, T. (2004). A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genetics, 36 (4), 337-8. doi:10.1038/ng1323

Huynh, H., Bottini, N., Williams, S., Cherepanov, V., Musumeci, L., Saito, K., Bruckner, S., Vachon, E., Wang, X., Kruger, J., Chow, C.-W., Pellecchia, M., Monosov, E., Greer, P. A., Trimble, W., Downey, G. P., & Mustelin, T. (2004). Control of vesicle fusion by a tyrosine phosphatase. Nature Cell Biology, 6 (9), 831-9. doi:10.1038/ncb1164

Junqueira, D.* , Cilenti, L.* , Musumeci, L., Sedivy, J., & Zervos, A. (January 2003). Random mutagenesis of PDZOmi domain and selection of mutants that specifically bind the Myc proto-oncogene and induce apoptosis. Oncogene, 22, 2772–2781. doi:10.1038/sj.onc.1206359